The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
Download PDF Brochure :
Vaccine adjuvants market is segmented into following types:
* On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016.
* On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016.
* On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others.
Speak to Analyst:https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=152603894
Some of The Major Players In Vaccine Adjuvants Market :
1. Brenntag Biosector (Denmark)
2. CSL Limited (Australia)
3. SEPPIC (France)
4. Agenus, Inc. (U.S.)
5. Novavax, Inc. (U.S.)
6. Invivogen (U.S.)
Get Sample Copy of This Report:https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894
Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.